Subcutaneous versus Intravenous Administration of Bortezomib in Multiple Myeloma


Subcutaneous versus Intravenous Administration of Bortezomib in Multiple Myeloma
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview with Rafael Fonseca, MD (12/22/10)

Moreau P et al. A phase 3 prospective, randomized, international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma. Proc ASH 2010;Abstract 312.

Dr Fonseca is Consultant and Professor of Medicine at the Mayo Clinic Arizona and Deputy Director of the Mayo Clinic Cancer Center in Scottsdale, Arizona.